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PHARMACOECONOMIC EFFICIENCY OF THE 
USE OF PROTEASE INHIBITORS FOR HOSPITAL 
INPATIENTS WITH AIDS
Rahmouni S, Peyron F, Flori A, Moreau J, Charbit JJ, Buès-
Charbit M, Balansard G
North Hospital, Marseilles, France
OBJECTIVE: Assessment of the impact of introduction of
protease inhibitors (April 1996) on the global expenditure
in an infectious unit providing classical hospitalization.
METHOD: A prospective study has been in progress
since 1990 in an AIDS unit (20 beds) of F. Houphouët
Boigny Hospital. All information was entered into a data-
base software (Microsoft Access 2.0) in order to facilitate
the data acquisition and the statistical analysis. Admis-
sions were classified according to 31 different diagnoses
in order to provide an average cost for each. 1558 pa-
tients (2717 admissions) were enrolled for whom drug
costs and details of hospitalization were analyzed.
RESULTS: In 1997, when the majority of inpatients were
receiving combination therapy using three antiretroviral
agents, we noticed a huge decrease in the number of pa-
tients and stays (41% and 45%, respectively, between
1995 and 1997). Correlating with these results, the total
drug cost dropped by a factor of 3, linked to a lower use
of antibiotics and oncology/immunology drugs in the
same period. However, this decrease must be interpreted
including costs of the antiretroviral therapy that is mainly
distributed in the daycare unit (multiplied by 5 between
1995 and 1997). The mean annual cost per stay de-
creased significantly (p  0.0376). During the same pe-
riod, the cost per prescription was relatively stable (296
FF in 1995 and 241 FF in 1997). All these findings are as-
sociated with a lower mean cost for some opportunistic
infections such as multiple infections (12,658 FF per stay
in 1992 and 2915 FF in 1997).
CONCLUSION: Our results highlight several interesting
points concerning treatment of HIV infection. Further
studies are needed taking into account the overall cost of
hospitalization in relation to improvement in the quality
of life.
PCA2
THE COST-EFFECTIVENESS OF ITRACONAZOLE 
SOLUTION IN THE TREATMENT OF ORAL 
CANDIDIASIS IN HIV/AIDS PATIENTS: AN 
INTERNATIONAL COMPARISON
McGann ME1, Halpern M1, Rance L2, Ajax MJ1
1MEDTAP International, Seattle, WA, US; 2Janssen-Ortho, Inc, 
North York, Ontario, Canada
OBJECTIVES: To compare the costs and outcomes of
therapy with itraconazole solution (IS) versus alternative
therapies in treating oral candidiasis (OC) in HIV/AIDS
patients in the US and Canada.
METHODS: Three clinical decision-analytic models were
developed for each country to evaluate the cost-effective-
ness of treating mild, moderate, and severe OC in HIV/
AIDS patients. Data for the models were derived from
published studies and a survey of American and Cana-
dian clinical experts. Outcomes included adverse events,
lack of response to therapy, relapse, and cure.
RESULTS: First-line treatments of mild OC in Canada
were nystatin suspension or nystatin suppository. Flucon-
azole replaced nystatin suspension in treating moderate
OC. Mild and moderate OC were treated with flucona-
zole and clotrimazole in the US. First-line treatments for
severe OC were fluconazole and ketoconazole in both
countries. The expected cost of treating each severity
level of OC was lower in Canada. In both countries, ther-
apy with IS yielded greater costs and cure rates than clot-
rimazole or nystatin, respectively, resulting in cost-effec-
tiveness values for IS of $125 to $1891 (all costs in 1998
US dollars). IS was dominant over fluconazole in Canada,
and had a cost-effectiveness ratio relative to fluconazole
of $300 to $364 in the US. Sensitivity analyses indicate
the above results were robust with respect to changes in
model parameters. 
CONCLUSIONS: Alternative therapies in both countries
for OC were different but model results were similar.
Treatment with itraconazole solution led to greater cure
rates in all scenarios, was cost-effective in the US, and
was cost-effective or cost-saving in Canada. As such, itra-
conazole solution is likely an appropriate choice for treat-
ing oral candidiasis in this population.
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